Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
On May 24, 2021, AbbVie announced that The Lancet published primary analysis results from pivotal Phase 3 clinical trials (Measure Up 1, Measure Up 2, and AD Up) assessing RINVOQ (upadacitinib) for treating moderate to severe atopic dermatitis in adults and adolescents. The studies demonstrated that RINVOQ met all primary and secondary endpoints, showcasing its efficacy and safety when compared to placebo. The results indicate potential advancements in treatment options for atopic dermatitis, affecting a significant percentage of the population.
AbbVie will participate in the UBS Global Healthcare Virtual Conference on May 25, 2021, at 11:00 a.m. Central time. Key executives participating include Michael Severino, Robert A. Michael, and Jeffrey R. Stewart. A live audio webcast will be available on AbbVie’s Investor Relations website, with an archived version accessible later the same day. AbbVie is dedicated to developing innovative medicines across various therapeutic areas such as immunology, oncology, and neuroscience.
AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 cancers at the ASCO Annual Meeting (June 4-8) and EHA Congress (June 9-17). Key presentations include data on the CAPTIVATE study concerning chronic lymphocytic leukemia (CLL) patients treated with an ibrutinib and venetoclax combination. Notable highlights include long-term data from various trials such as CLL14 and MURANO. These presentations aim to advance blood cancer treatment and showcase AbbVie's expanding oncology portfolio, reflecting its commitment to improving patient outcomes.
AbbVie (NYSE: ABBV) will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 3:50 p.m. Central time. Key executives, including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, will participate in the virtual event. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later that day. AbbVie focuses on innovative medicines in immunology, oncology, neuroscience, and more.
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), announced the acquisition of Soliton (NASDAQ: SOLY) for $22.60 per share, valuing the deal at approximately $550 million. The acquisition includes Soliton's FDA-cleared RESONIC™ device, which offers a non-invasive treatment for cellulite. This technology enhances Allergan’s body contouring portfolio, complementing its existing products like CoolSculpting®. The transaction is subject to regulatory approvals and shareholder consent.
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced an agreement to acquire Soliton (NASDAQ: SOLY) for $22.60 per share in cash, valuing the transaction at approximately $550 million. This acquisition aims to enhance Allergan's portfolio with Soliton's RESONICTM device, which has received FDA 510(k) clearance as a non-invasive cellulite treatment. The deal, approved by both companies' boards, is subject to customary closing conditions. Allergan's established market presence is expected to maximize the commercial potential of Soliton's technology.
AbbVie reported strong first-quarter results for 2021, with worldwide GAAP net revenues of $13.010 billion, up 51%. Adjusted net revenues increased 5.2% to $12.935 billion. The immunology portfolio contributed $5.744 billion. Notable products include Humira with revenues of $4.867 billion, and Skyrizi at $574 million. AbbVie anticipates multiple product approvals in 2021, raising full-year GAAP diluted EPS guidance to $6.89-$7.47 and adjusted EPS to $12.37-$12.57.
Allergan, a subsidiary of AbbVie (NYSE: ABBV), will present new data on its eye care portfolio at the 2021 ARVO Annual Virtual Meeting from May 1-7. This includes patient-reported outcomes for AGN-190584, an investigational treatment for presbyopia, for which a New Drug Application has been submitted to the FDA. Key presentations will cover the effectiveness of DURYSTA™ in lowering intraocular pressure and real-world data from the multicenter EXPAND study involving the XEN® Gel Stent. The meeting will showcase advancements in treating challenging eye conditions.
AbbVie (NYSE: ABBV) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for VENCLYXTO® (venetoclax) combined with hypomethylating agents to treat adults with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy. This recommendation supports AbbVie’s mission to enhance treatment options for patients facing this aggressive cancer. The final decision from the European Commission is anticipated in the first half of 2021, following promising trial results indicating improved survival rates.
AbbVie has submitted applications to the FDA and EMA for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis. These submissions are based on two pivotal Phase 3 trials, KEEPsAKE-1 and KEEPsAKE-2, demonstrating significant improvements in disease activity and skin clearance at week 24. SKYRIZI, an IL-23 inhibitor, aims to provide effective treatment for patients who have not responded to other therapies. The safety profile remains consistent with previous studies, showing no new risks.